Author, Subjects, Keywords

Cited Author

 
 
   » By Author or Editor
 » Browse Author by Alphabet
 » By Journal
 » By Subjects
 » By Affiliations
 » By Type
 » By Year
 » By Latest Additions
 
 
   » By Author
 » Top 20 Authors
 » Top 20 Article
 » Top 20 Journal Cited
 » Top 20 Cited
 » Top 20 Author Cited
 » Usage Since Sept 2007


 
 
 

Login | Create Account

An Overview on the Development of Newcastle Disease Virus as an Anti-Cancer Therapy.

Abdul Rahman Omar, and Aini Ideris, and Abdul Manaf Ali, and Fauziah Othman, and Khatijah Yussoff, and Jafri Malin Abdullah, and Haryati Shila Mohamad Wali, and Madiha Zawawi, and Meyyappan, N. (2003) An Overview on the Development of Newcastle Disease Virus as an Anti-Cancer Therapy. Malaysian Journal of Medical Sciences, 10 (1). pp. 4-12. ISSN 1394195X

Full text not available from this repository.

Official URL: http://www.medic.usm.my/publication/mjms/

Affiliations

Universiti Putra Malaysia, Institute of Bioscience
Universiti Putra Malaysia, Faculty of Veterinary Medicine
Universiti Putra Malaysia, Institute of Bioscience
Universiti Putra Malaysia, Faculty of Medicine and Health Sciences
Universiti Putra Malaysia, Faculty of Science and Environmental Studies
Universiti Sains Malaysia, School of Medical Sciences
Universiti Putra Malaysia, Faculty of Veterinary Medicine
Universiti Putra Malaysia, Institute of Bioscience
Universiti Putra Malaysia, Faculty of Medicine and Health Sciences

Abstract

Newcastle disease virus (NDV) is one of the most economically important avian virus which affects the poultry industry worldwide. Although NDV is being very actively studied in Malaysia, there are still no studies on its potential as an anticancer agent, a new approach to treating cancer known as virotherapy. Currently, a collaborative research is being undertaken between Universiti Putra Malaysia (UPM), Universiti Sains Malaysia (USM) and Majlis Kanser Nasional (MAKNA) in characterising various local NDV isolates as anticancer agent. This paper describes an overview of the research that have been carried out worldwide in the use of NDV for cancer treatment and also some of our findings in characterising local NDVs with oncolytic properties.

Item Type:Journal
Additional Information:This study is a collaborative project between UPM and USM which is funded by National Cancer Council (MAKNA).
Keywords:Newcastle disease virus, anticancer agent, apoptosis. veterinary medicine
Subjects:R Medicine
ID Code:885

1) Ackermann, W. and Kurtz, H. A new host-virus system. Proc Soc Exp Biol 1952; 8: 421-423.

2) Aini, I. The control of Newcastle disease – A review. Jurnal Vet Malaysia 1990; 2:1-13.

3) Annual Report 1997 - Cancer. Ministry of Health, Malaysia.

4) Anton, P., Kirchner, H., Jonas, U. and Atzpodien, J. Cytokines and tumour vaccination. Cancer Biother Radiopharm 1996; 11: 315-318.

5) Ahlert, T., Sauerberi, W., Bastert, G., Ruhland, S., Bartik, B., Simiantonaki, N., Schumacher, J., Hacker, B., Schumacher, M. and Schirrmacher, V. Tumour-cell number and viability as quality and efficacy parameters of autologous virus-modified cancer vaccines in patients with breast or ovarian cancers. J Clin Oncol 1997; 15: 1354-1365.

6) Asada, T. Treatment of human cancer with mumps virus. Cancer 1974; 34: 1907-1928.

7) Bohle, W., Schlag, P., Liebrich, W., Hohenberger, P., Manasterski, M., Möller, P. and Schirrmacher, V. Postoperative active specific immunization in colorectal cancer patients with virus-modified autologous tumour-cell vaccine. Cancer 1990; 66:1517-1523.

8) Cassel, W.A. and Garrett, R.E. Newcastle disease virus as an antineoplastic agent. Cancer 1965; 18: 863-868.

9) Cassel, W.A., Murray, D.R. and Phillips, H.S. A phase II study on the postsurgical management of stage II malignant melanoma with a Newcastle disease virus oncolysate. Cancer 1983; 52: 856-860.

10) Cassel, W.A., Murray, D.R., Torbin, A.H., Olkowski, Z.L. and Moore, M.E. Viral oncolysate in the management of malignant melanoma. I. Preparation of the oncolysate and measurement of immunologic responses. Cancer 1977; 40: 672-679.

11) Castary, L.K. and Bakacs, T. Use of Newcastle disease virus vaccine (MTH-68/H) in a patient with high-grade glioblastoma. JAMA 1999; 281: 1588-1589.

12) Coffey, M.C., Strong, J.E., Forsyth, P.A. and Lee, P.W.K. Reovirus therapy of tumours with activated ras pathway. Science 1998; 282: 1332-1334.

13) Connolly, J.L., Barton, E.S. and Dermody, T.S. Reovirus binding to cell surface sialic acid potentiates virus-induced apoptosis. J Virol 2001; 75: 4029-4039.

14) Csatary, L.K., Moss, R.W., Beuth, J., Torocsik, B., Szeberenyi, J. and Bakacs, T. Beneficial treatment of patients with advanced cancer using a Newcastle disease virus vaccine (MTH-68/H). Anticancer Res 1998; 19: 635-638.

15) de Leeuw, O. and Peeters, B. Complete nucleotide sequence of Newcastle disease virus: evidence for the existence of a new genus within the subfamily Paramyxovirinae. J Gen Virol 1999; 80: 131-136.

16) Doyle, T.M. A hitherto unrecorded disease of fowls due to a filter passing virus. J Comp Path Therap 1927; 40: 144-169.

17) Fábián, Z., Töröcsik, B., Kiss, K., Csatary, L.K., Bodey, B., Tigyi, J., Csatary, C. and Szeberényi, J. Induction of apoptosis by a Newcastle disease virus vaccine

(MTH-68/H) in PC12 rat phaeochromocytoma cells. Anticancer Res 2002; 21: 125-136.

18) Fauziah, O., Omar, A.R., Patimah, I. and Aini, I. Microscopic evaluation of Newcastle disease virus (NDV) a killer in chicken but a possible live saver in human. J Elect Micro Soc Thailand 2002; 16: 272.

19) Flanagan, A.D., Love, R., Tesar, W. Propagation of Newcastle disease virus in Ehrlich ascites cells in vitro and in vivo. Proc Soc Biol Med 1955; 90: 1323-1333.

20) Galanis, E., Vile, R. and Russel, S.K. 2002. Delivery systems intended for in vivo gene therapy of cancer: targeting and replication competent viral vectors. Crit Review in Oncol Hematol 2002; 38: 177-192.

21) Khatijah Yusoff and Wen Siang Tan. Newcastle disease virus: macromolecules and opportunities. Avian Pathol 2001; 30: 439-455.

22) Kho, C.L., Mohd-Azmi, M.L., Arshad, S.S. and Yusoff, K. Performance of an RT-nested PCR ELISA for detection of Newcastle disease virus. J Virol Meth 2000; 86: 71-83.

23) Kirchner, H.H., Anton, P., Atzpodien, J. Adjuvant treatment of locally advanced renal cell cancer with autologous virus-modified tumour vaccines. World J Urol 1995; 13; 171-173.

24) Kirn, D., Niculescu-Duvaz, I., Hallden, G. and Springer, G.J. The emerging fields of suicide gene therapy and virotherapy. Trends in Mol Med 2002; 8:S68-S73.

25) Kraneveld, F.C. A poultry disease in the Dutch East Indies. Ned Indisch B1 Diergeneesk 1926; 38: 448-450.

26) Liang, W., Wang, H., Sun, T.M., Yao, W.Q., Jin, Y., Li, C.L. and Meng, F.J. Application of autologous tumour cell vaccine and NDV vaccine in treatment of tumours of digestive tract. World J Gastroenterol 2003; 9: 495-498.

27) Lorence, R.M., Katubig, B.B., Reichard, K.W., Reyes, H.M., Phuangsab, A., Sassetti, M.D., Walter, R.J. and Peeples, M.E. Complete regression of human fibrosarcoma xenografts after local Newcastle Disease Virus therapy. Cancer Res 1994a; 54: 6017-6021.

28) Lorence, R.M., Reichard, K.W., Katubig, B.B., Reyes, H.M., Phuangsab, A., Mitchell, B.R., Cascino, C.J., Walter, R.J. and Peeples, M.E. Complete regression of human neuroblastoma xenografts in athymic mice after local Newcastle disease virus therapy. J Nat Cancer Inst 1994b; 86: 1228-1233.

29) Martin, S.J. Apoptosis: An introduction. In Apoptosis and Cancer. Martin, S.J., ed. Karger Landes Systems, 1997; 9-24.

30) Mebatsion, T., Koolen, M.J.M, de Vaan, L.T.C., de Haas, N., Braber, M., Romer-Oberdorfer, A., van den Elzen, P. and van der Marel, P. Newcastle disease virus (NDV) marker vaccine: an immunodominant epitope of the nucleoprotein gene of NDV can be deleted or replaced by a foreign epitope. J Virol 2002; 76: 10138-10146.

31) Nor Faizah, A.H., Maswati, M.A., Asiah, H.M., Roslan, M., Zabidah, A. and Abd Rahim A. Re-emergence of velogenic Newcastle disease virus in Malaysia. In: 2nd International Congress/13th VAM Congress and CVAAustralasia/Oceania Symposium, Kuala Lumpur,Malaysia, 27-30 August, 2001. pp 86-87.

32) Norman, K.L., Farassati, F. and Lee, P.W.K. Oncolytic virus and cancer therapy. Cyto Growth Fact Review 2001; 12: 271-282.

33) O’Brien, V. Viruses and apoptosis. J Gen Virol 1998; 79: 1833-1845.

34) Pecora, A.L., Rizvi, N., Cohen, G.I., Meropol, N.J., Sterman, D., Marshall, J.L., Goldberg S., Gross, P., O’Neil, J.D., Groene, W.S., Roberts, M.S., Rabin, H., Bamat, M.K. and Lorence, R.M. Phase I trial of intravenous administration of PV701, an oncolytic virus, in patients with advanced solid cancers. J Clin Oncol 2002; 20: 2251-2266.

35) Phuangsab, A., Lorence, R.M., Reichard, K.W., Peeples, M.E. and Walter, R.J. Newcastle disease virus therapy of human tumour xenografts: antitumour effects of local or systemic administration. Cancer Letters 2001; 172: 27-36.

36) Plaksin, D., Porgador, A., Vadai, E., Feldman, M., Schirrmacher, V. and Eisenbach, L. Effective antimetastatic

melanoma vaccination with tumour cells transfected with MHC genes and/or infected with Newcastle disease virus (NDV). Int J Cancer 1994;59: 796-801.

37) Rabu, A., Tan, W.S., Kho, C.L., Omar, A.R. and Yusoff, . Chimeric Newcastle disease virus nucleocapsid with parts of viral hemagglutinin-neuraminidase and fusion proteins. Acta Virol 2002; 46: 211-217.

38) Ramanujuam, P., Tan, W.S., Nathan, S. and Yusoff, K. Novel peptides that inhibit the propagation of Newcastle disease virus. Arch Virol 2002; 147: 981-993.

39) Reichard, K.W., Lorence, R.M., Cascino, C.J., Peeples, M. E., Walter, R.J., Fernando, M.B., Reyes, H.M. and Greager, J.A. Newcastle disease virus selectively kills human tumour cells. J Surg Res 1992: 52: 448-453.

40) Ring, C.J.A. Cytolytic viruses as potential anti-cancer agents. J Gen Virol 2002; 83: 491-502.

41) Romer-Oberdorfer, A., Mundt, M., Mebatsion, T., Buchholz, U.J. and Mettenleiter, T.C. Generation of recombinant lentogenic Newcastle disease virus from cDNA. J Gen Virol 1999; 80: 2987-2995.

42) Schild, H., von Hoegen, P. and Schirrmacher, V. Modification of tumour cells by a low dose of Newcastle disease virus. II. Augmented tumourspecific T cell response as a result of CD4+ and CD8+ immune T cell cooperation. Cancer Immunol Immunother 1989; 28: 22-28.

43) Shimizu, Y., Hasumi, K., Okadaira, Y., Yamainishi, K. and Takahashi, M. Immunotherapy of advanced gynecologics cancer patients utilizing mumps virus. Cancer Detect Prev 1988; 12:487-495.

44) Schirrmacher, V. Immunity and metastasis: In situ activation of protective T cells by virus modified cancer vaccines. Cancer Surveys 1992; 1: 128-154.

45) Schirrmacher, V. Newcastle disease virus in tumour therapy. Program booklet from “cytoreductive gene therapy”. Harold W. Siebens Conferences, Sept 25-27, 1999, Rochester, MN.

46) Schirrmacher, V., Ahlert, T., Probstle, T., Steiner, H., Herold-Mende, C., Gerhards, R., Hagmuller, E. and Steiner, H.H. Immunization with virus-modified tumour cells. Sem Oncol 1998; 25: 677-696.

47) Schirrmacher, V., Bai, L., Umansky, V., Yu, L., Xing, Y. and Qian, Z. Newcastle disease virus activates macrophages for anti-tumour activity. Int J Oncol 2000; 16: 363-373.

48) Schirrmacher, V., Griesbach, A. and Ahlert, T. Antitumour effects of Newcastle disease virus in vivo: local versus systemic effects. Int J Oncol 2001; 18:945-52.

49) Schirrmacher ,V., Haas, C., Bonifer, R., Ahlert, T., Gerhards, R. and Ertel, C. Human tumour cell modification by virus infection: an efficient and safe way to produce cancer vaccines with pleiotropic immune stimulatory properties when using Newcastle Disease Virus. Gene Therapy 1999; 6: 63-73.

50) Sinkovics, J.G. and Horvath, J. Newcastle disease virus(NDV): brief history of its oncolytic strains. J Clin Virol 2000; 16: 1-15.

51) Stone-Hulslander, J. and Morrison, T.G. Detection of an interaction between the HN and F proteins in Newcastle disease virus virus-infected cell. J Virol 1997; 71: 6287-6295.

52) Teodoro, J.G. and Branton, P.E. Regulation of apoptosis by viral gene products. J Virol 1997; 71: 1739-1746.

53) Tzadok-David, Y., Metzkin-Eizenberg, M. and Zakay-Rones Z. The effect of a mesogenic and lentogenic Newcastle disease virus strain on Burkitt lymphoma Daudi cells. J Cancer Res Clin Oncol 1995; 121: 169-174.

54) Washburn, B., Weigand, M.A., Grosse-Wilde, A., Janke, M., Stahl, H., Rieser, E., Sprick, M.R., Schirrmacer, V. and Walczak, H. TNF-related apoptosis-inducing ligand mediates tumouricidal activity of human monocytes stimulated by Newcastle disease virus. J Immunol 2003; 170: 1814-1821.

55) Zeng, J., Fournier, P. and Schirrmacher, V. Stimulation of human natural interferon-_ response via

paramyxovirus hemagglutinin lectin-cell interaction. J Mol Med 2002a; 80: 443-451.

56) Zeng, J., Fournier, P. and Schirrmacher, V. Induction of interferon-alpha and tumour necrosis factor-related apoptosis-inducing ligand in human blood mononuclear cells by hemagglutinin-neuraminidase but not F protein of Newcastle disease virus. Virology 2002b; 297: 19-30.

57) Zorn, U., Dallman, I., Grosse, J., Kirchner, H., Poliwoda, H. and Atzpodien, J. Induction of cytokines and cytotoxicity against tumour cells by Newcastle disease virus. Cancer Biother 1994; 9: 225-235.

58) Zwiebel, J.A. Cancer gene and oncolytic virus therapy. Sem Oncol 2001; 28: 336-343.

Repository Staff Only: item control page
 
 
 
 
 
   
© Copyright 2007 MyAIS Faculty of Computer Science and Information Technology, University of Malaya – All Rights Reserved. Malaysian Abstracting and Indexing System is powered by EPrints 3 which is developed by the School of Electronics and Computer Science at the University of Southampton. More information and software credits.